This site is intended only for healthcare professionals resident in Egypt 




Sign InLog Out Our medicinesTherapy areasExplore contentExplore contentEventsDownloadable materialsVideosLet’s connectLet's ConnectContact Us



Clinical Information Clinical Information Burden of meningococcal disease Serogroup distribution Nimenrix® immunogenicity Nimenrix® persistence Nimenrix® dose and administration Real-world impact Summary Important Safety Information Abbreviated Prescribing Information Support and Services Support and Services VideosWebinarsSelf-detail Presentations

Serogroup distribution

Global data

The distribution of meningococcal serogroups varies across countries.2


Almost half of the invasive meningococcal disease cases worldwide are caused by serogroups A, C, W and Y15

Burden of MenW

The incidence of MenW, a serogroup often associated with high fatality, has been increasing.16

Recently, surges of MenW incidence with cases of a hypervirulent strain have been associated with invasive meningococcal disease and higher fatality rates compared with other serogroups.16

Adapted from Booy et al, 2019.

MenW is often associated with higher fatality rates compared with other serogroups.17

MenW has emerged with high case fatality

Adapted from Villena R, et al. Vaccine. 2019; Presa JV, et al. Int J Infect Dis. 2019;
Loenenbach AD, et al. Clin Infect Dis. 2020; Ladhani SN, et al. Clin Infect Dis. 2015; Australian DOH. Invasive Meningococcal Disease National Surveillance Report with a Focus on MenW. 2017.

Find out moreLoading
Find out moreLoading
Find out moreLoading

*“Other” includes serogroups other than A, B, C, W, and Y and cases where the serogroup was not determined; with the exception of the EU and US, which also included serogroup A.
Percent value indicates the proportion of meningococcal disease caused by MenW.
Values rounded
§England only

NT, non-typeable; MenW, meningococcal serogroup W; IMD, invasive meningococcal disease


  1. Stein-Zamir C, Shoob H, Sokolov I, Kunbar A, Abramson N, Zimmerman D. The clinical features and long-term sequelae of invasive meningococcal disease in children. Pediatr Infect Dis J. 2014;33(7):777-779.
  2. Halperin SA, Bettinger JA, Greenwood B, et al. The changing and dynamic epidemiology of meningococcal disease. Vaccine. 2012;30 Suppl 2:B26-B36.
  3. Tsang RS, Hoang L, Tyrrell GJ, et al. Increase in ST-11 serogroup W Neisseria meningitidis invasive meningococcal disease in Canada, 2016-2018. Can Commun Dis Rep. 2019;45(6):164-169.
  4. Center for Disease Control and Prevention (CDC). Active Bacterial Core Surveillance Report, Emerging Infections Program Network,  Neisseria meningitidis, 2018. Accessed August 5, 2022.
  5. European Centre for Disease Control and Prevention (ECDC). ECDC Surveillance Report  2017. Accessed August 5, 2022.
  6. MenAfriNet. WHO Meningitis Weekly Bulletin. Week 49–52, 2019. Accessed August 5, 2022.
  7. NICD, GERMS-SA Surveillance Review 2019. Accessed August 5, 2022.
  8. Memish Z, Al Hakeem R, Al Neel O, Danis K, Jasir A, Eibach D. Laboratory-confirmed invasive meningococcal disease: effect of the Hajj vaccination policy, Saudi Arabia, 1995 to 2011. Euro Surveill. 2013;18(37):20581.
  9. Koroleva I. Invasive Meningococcal Disease in Russian Federation. Paper presented at: 14th Congress of the EMGM, European Meningococcal and Haemophilus Disease Society; September 18–21, 2017; Prague, Czech Republic.
  10. Zhou H, Gao Y, Xu L, et al. Distribution of serogroups and sequence types in disease-associated and carrier strains of Neisseria meningitidis isolated in China between 2003 and 2008. Epidemiol Infect. 2012;140(7):1296-1303.
  11. Lahra MM, Hogan TR; National Neisseria Network, Australia. Australian Meningococcal Surveillance Programme annual report, 2019. Commun Dis Intell. (2018). 2020;44. doi: 10.33321/cdi.2020.44.62
  12. Gómez JA, Wetzler Malbrán P, Vidal G, Seoane M, Giglio ND. Estimation of the real burden of invasive meningococcal disease in Argentina. Epidemiol Infect. 2019;147:e311.
  13. Villena R, Valenzuela MT, Bastías M, Santolaya ME. Meningococcal invasive disease by serogroup W and use of ACWY conjugate vaccines as control strategy in Chile. Vaccine. 2019;37(46):6915-6921.
  14. Presa JV, de Almeida RS, Spinardi JR, Cane A. Epidemiological burden of meningococcal disease in Brazil: A systematic literature review and database analysis. Int J Infect Dis. 2019;80:137-146.
  15. Purmohamad A, Abasi E, Azimi T, et al. Global estimate of Neisseria meningitidis serogroups proportion in invasive meningococcal disease: A systematic review and meta-analysis. Microb Pathog. 2019;134:103571.
  16. Booy R, Gentile A, Nissen M, Whelan J, Abitbol V. Recent changes in the epidemiology of Neisseria meningitidis serogroup W across the world, current vaccination policy choices and possible future strategies. Hum Vaccin Immunother. 2019;15(2):470-480.
  17. Meningitis Research Foundation. Meningococcal group W (menW). Accessed August 5, 2022.
  18. Loenenbach AD, van der Ende A, de Melker HE, Sanders EAM, Knol MJ. The Clinical Picture and Severity of Invasive Meningococcal Disease Serogroup W Compared With Other Serogroups in the Netherlands, 2015-2018. Clin Infect Dis. 2020;70(10):2036-2044.
  19. Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60(4):578-585.
  20. Australian DOH. Invasive Meningococcal Disease National Surveillance Report with a Focus on MenW. Published January 9, 2017. Accessed August 5, 2022.
Click here for Nimenrix® Prescribing Information Loading

Approval Code: BF0098OA686/052023
Invalidation date: 10/05/2025


Adverse events should be reported. Adverse events can be reported to [email protected]

PfizerPro AccountPfizerPro Account

To access further materials, resources and receive communication about medicines and vaccines promoted by Pfizer.

Sign inRegisterAccountSign Out

The product information provided in this site is intended only for Healthcare Professionals of Egypt. The products discussed herein may have different product labeling in different countries. 


Copyright © 2023 Pfizer biopharmaceutical LLC. All rights reserved.


For Healthcare Professionals only

These pages are not intended for patients or members of the general public. This portal contains healthcare promotional content.

If you select ‘No’, you will be redirected to, the global Pfizer website.

I confirm that I am a healthcare professional resident in Egypt.


Yes No
You are leaving the Pfizer for Professionals website
You are being directed to a third-party website:

This link is provided for your convenience. Please note that this third-party website is not controlled by Pfizer for Professionals or subject to our privacy policy.